Rest of world — Total Revenue
Moderna Rest of world — Total Revenue remained flat by 0.0% to $173.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 18.9%, from $213.25M to $173.00M. Over 4 years (FY 2021 to FY 2025), Rest of world — Total Revenue shows a downward trend with a -40.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful international market penetration and growing global demand for the company's products, while a decrease may signal competitive pressure or regulatory challenges in foreign territories.
Detailed definition
This metric represents the total gross revenue generated by the company from all geographic regions excluding the primar...
Peer comparison
Peers in the biotech and pharmaceutical sectors typically report geographic revenue splits to demonstrate global commercial reach and regulatory success in diverse jurisdictions.
mrna_segment_rest_of_world_total_revenueHistorical Data
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $5.45B | $7.30B | $3.60B | $853.00M | $692.00M |
| YoY Change | — | +34.0% | -50.7% | -76.3% | -18.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Moderna's rest of world — total revenue?
- Moderna (MRNA) reported rest of world — total revenue of $173.00M in Q4 2025.
- How has Moderna's rest of world — total revenue changed year-over-year?
- Moderna's rest of world — total revenue decreased by 18.9% year-over-year, from $213.25M to $173.00M.
- What is the long-term trend for Moderna's rest of world — total revenue?
- Over 4 years (2021 to 2025), Moderna's rest of world — total revenue has grown at a -40.3% compound annual growth rate (CAGR), from $5.45B to $692.00M.
- What does rest of world — total revenue mean?
- Total sales revenue earned from all countries outside the company's home market.